AR105662A1 - Derivados de piridina y de pirimidina como inhibidores del eaat3 - Google Patents

Derivados de piridina y de pirimidina como inhibidores del eaat3

Info

Publication number
AR105662A1
AR105662A1 ARP160102450A ARP160102450A AR105662A1 AR 105662 A1 AR105662 A1 AR 105662A1 AR P160102450 A ARP160102450 A AR P160102450A AR P160102450 A ARP160102450 A AR P160102450A AR 105662 A1 AR105662 A1 AR 105662A1
Authority
AR
Argentina
Prior art keywords
methyl
cyclopropyl
cyano
ethyl
eaat3
Prior art date
Application number
ARP160102450A
Other languages
English (en)
Spanish (es)
Inventor
Wichmann Juergen
Hoener Marius
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR105662A1 publication Critical patent/AR105662A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP160102450A 2015-08-12 2016-08-10 Derivados de piridina y de pirimidina como inhibidores del eaat3 AR105662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15180759 2015-08-12

Publications (1)

Publication Number Publication Date
AR105662A1 true AR105662A1 (es) 2017-10-25

Family

ID=53835950

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102450A AR105662A1 (es) 2015-08-12 2016-08-10 Derivados de piridina y de pirimidina como inhibidores del eaat3

Country Status (7)

Country Link
US (1) US10005736B1 (enExample)
EP (1) EP3334727B1 (enExample)
JP (1) JP6754828B2 (enExample)
CN (1) CN107922391B (enExample)
AR (1) AR105662A1 (enExample)
TW (1) TW201718499A (enExample)
WO (1) WO2017025523A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6518789B2 (ja) 2015-04-23 2019-05-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 精神障害の処置において使用するためのテトラゾール誘導体
WO2017060202A1 (en) 2015-10-06 2017-04-13 F. Hoffmann-La Roche Ag Triazole derivatives
JP6849668B2 (ja) * 2015-10-28 2021-03-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ピリジン又はピリミジン誘導体
EP3411365B1 (en) 2016-02-02 2019-11-20 H. Hoffnabb-La Roche Ag Pyrazol-pyridine derivatives as eaat3 inhibitors
WO2017202896A1 (en) 2016-05-27 2017-11-30 F. Hoffmann-La Roche Ag Pyrazol compounds as eaat3 inhibitors
WO2018069362A1 (en) 2016-10-14 2018-04-19 F. Hoffmann-La Roche Ag Imidazole compounds as eaat3 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2069313A2 (en) * 2006-06-29 2009-06-17 Alantos Pharmaceuticals Holdings, Inc. Metalloprotease inhibitors
WO2010033168A2 (en) * 2008-09-18 2010-03-25 Renovis, Inc. Amide compounds, compositions and uses thereof
CN102271682B (zh) * 2008-10-31 2015-12-16 默沙东公司 用于治疗疼痛的p2x3受体拮抗剂

Also Published As

Publication number Publication date
CN107922391A (zh) 2018-04-17
JP2018522916A (ja) 2018-08-16
HK1251226A1 (zh) 2019-01-25
JP6754828B2 (ja) 2020-09-16
US20180162824A1 (en) 2018-06-14
EP3334727A1 (en) 2018-06-20
WO2017025523A1 (en) 2017-02-16
US10005736B1 (en) 2018-06-26
EP3334727B1 (en) 2019-05-15
TW201718499A (zh) 2017-06-01
CN107922391B (zh) 2020-09-25

Similar Documents

Publication Publication Date Title
AR105662A1 (es) Derivados de piridina y de pirimidina como inhibidores del eaat3
AR104331A1 (es) Derivados de tetrazol
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2018000036A1 (es) Derivados etinilo
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
MX374296B (es) Compuestos de pirazina novedosos para el tratamiento de enfermedades infecciosas
EA201691302A1 (ru) Новые гетероциклические соединения
PE20191496A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MX2017010062A (es) [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
MX2018003590A (es) Compuestos y metodos para la inhibicion de jak.
AR098522A1 (es) Compuesto de triazolo-piridina
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
MX2020001157A (es) Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).
AR099047A1 (es) Derivados etinilo
AR104863A1 (es) Derivados imidazol
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
CL2019000462A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional solicitud 201603258)
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
AR105327A1 (es) Derivados de imidazol
AR107490A1 (es) Derivados de pirazol-piridina como inhibidores de eaat3

Legal Events

Date Code Title Description
FB Suspension of granting procedure